Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

Gynecologic Oncology

Volumn 121, Issue 2, 2011, Pages 269-272

  O'Malley, David M ^a,b   Richardson, Debra L ^a   Rheaume, Patrick S ^a   Salani, Ritu ^a   Eisenhauer, Eric L ^a   McCann, Georgia A ^a   Fowler, Jeffrey M ^a   Copeland, Larry J ^a   Cohn, David E ^a   Backes, Floor J ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b M 210 Starling Loving Hall ^*  (United States)

Author keywords

Bevacizumab; Chemotherapy; Recurrent ovarian cancer; Treatment; Weekly paclitaxel

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CYTOKINE; ERYTHROCYTE STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG SENSITIVITY; EPITHELIAL OVARY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MEDICAL RECORD REVIEW; NEUROPATHY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 79955477996     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.01.009     Document Type: Article

References (20)

1. D. Belotti, V. Vergani, and T. Drudis The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 11 Nov 1996 1843 1849 (Pubitemid 26384151)
2. D.H. Lau, L. Xue, L.J. Young, P.A. Burke, and A.T. Cheung Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer Cancer Biother Radiopharm 14 1 Feb 1999 31 36 (Pubitemid 29157732)
3. L. Byrd, F.C. Thistlethwaite, A. Clamp, C. Ton, J. Hasan, and G.C. Jayson Weekly paclitaxel in the treatment of recurrent ovarian carcinoma Eur J Gynaecol Oncol 28 3 2007 174 178 (Pubitemid 46985636)
4. T. Le, L. Hopkins, K.A. Baines, L. Rambout, M. Al Hayki, and M.F. Kee Fung Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer Gynecol Oncol 102 1 Jul 2006 49 53 (Pubitemid 43851048)
5. J. Kaern, M. Baekelandt, and C.G. Trope A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients Eur J Gynaecol Oncol 23 5 2002 383 389 (Pubitemid 35364663)
6. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a gynecologic oncology group study Gynecol Oncol 101 3 Jun 2006 436 440 (Pubitemid 43729968)
7. M. Linch, F. Stavridi, J. Hook, Y. Barbachano, M. Gore, and S.B. Kaye Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 1 Apr 2008 27 32
8. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 25 33 Nov 20 2007 5165 5171 (Pubitemid 350237599)
9. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 Nov 20 2007 5180 5186 (Pubitemid 350232248)
10. B.J. Monk, E. Han, C.A. Josephs-Cowan, G. Pugmire, and R.A. Burger Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer Gynecol Oncol 102 2 Aug 2006 140 144 (Pubitemid 44056265)
11. J.D. Wright, A.A. Secord, and T.M. Numnum A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer Int J Gynecol Cancer 18 3 May-Jun 2008 400 406
12. D.L. Richardson, F.J. Backes, and L.G. Seamon Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer Gynecol Oncol 111 3 Dec 2008 461 466
13. E.S. Han, and B.J. Monk Bevacizumab in the treatment of ovarian cancer Expert Rev Anticancer Ther 7 10 Oct 2007 1339 1345 (Pubitemid 351826900)
14. L.M. Randall, and B.J. Monk Bevacizumab toxicities and their management in ovarian cancer Gynecol Oncol Apr 1 2010
15. D.L. Richardson, F.J. Backes, and J.D. Hurt Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol Apr 9 2010
16. J.D. Hurt, D.L. Richardson, and L.G. Seamon Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer Gynecol Oncol 115 3 Dec 2009 396 400
17. A.E. Guppy, and G.J. Rustin CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 7 5 2002 437 443 (Pubitemid 35266136)
18. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 19 20 Oct 15 2001 4054 4057 (Pubitemid 32976692)
19. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 Feb 2 2000 205 216
20. D.E. Cohn, K. Kim, K. Resnick, D.M. O'Malley, and J.M. Straughn Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis Gynecol Oncol 116 2010 S12 S13